Exicure (NASDAQ: XCUR) announced that Annals of Hematology has published results from a Phase 2 clinical study demonstrating rapid stem cell mobilization with burixafor (GPC-100/TG-0054)—a highly selective CXCR4 inhibitor—in patients with multiple myeloma and lymphoma undergoing transplant.
According to Exicure, Phase 2 data demonstrate differentiated CXCR2 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant.
In a statement, Michael Schuster, MD, clinical professor of medicine at Stony Brook University and a study author, commented, “ASCT remains a treatment cornerstone for multiple myeloma and certain lymphomas. Efficient mobilization of peripheral blood progenitor cells is critical to achieving reliable engraftment while minimizing patient burden and overall healthcare costs. In this study, burixafor demonstrated enhanced mobilization kinetics that led to significantly faster attainment of stem cell collection goals, highlighting its differentiated profile and potential to meaningfully improve the efficiency of cell collection for ASCT. Beyond transplant, rapid and predictable mobilization of CD34-positive cells and lymphocytes may also be highly relevant for emerging gene-based and gene-editing approaches, including those being explored for conditions such as sickle cell disease.”
